Dr. Ellen V. Stevens’ career in government, academics, and industry has focused on identification and development of novel targeted therapies and screening modalities for newborn illnesses and cancer. At the National Cancer Institute (NCI), she worked collaboratively between departments to develop reverse-phase protein lysate microarrays for the prediction of drug sensitivity in ovarian cancer patients. Her dissertation research included exploring nitric oxide-releasing nanoparticles as a potential targeted therapy for ovarian cancer. Additionally, she studied the role, regulation and mechanism of RhoGDI2 in ovarian cancer. Her work at Memorial Sloan Kettering Cancer Center (MSKCC) focused on the genomic complexity of AKT in ovarian and breast cancer. At Duke University she studied the role of estrogen-related receptors in ovarian cancer. She has held a variety of positions at small and large biotech companies, primarily developing novel microfluidic enzymatic and immunoassay devices for point-of-care biomarker testing. Most recently, she worked in public health developing methodologies utilizing next generational sequencing platforms for screening newborns. In her free time, Dr. Stevens loves hiking and camping with her family.
Education: B.S. in Biology with minor in Chemistry from Virginia Polytechnic Institute and State University; Ph.D. in Pharmacology from University of North Carolina at Chapel Hill